Orexo announces data from the MODIA study evaluating impact on use of illicit opioids

UPPSALA, Sweden, Oct. 11, 2023. Orexo AB, today reports top-line results after having completed a study evaluating the efficacy of MODIA in combination with sublingual buprenorphine/ naloxone for the treatment of opioid use disorder (OUD) and...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials